Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: A single-centre experience

References

• Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325–32.
   PubMed Web of Science ®Google Scholar
• Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163:1632–42.
   PubMed Web of Science ®Google Scholar
• Kreftregisteret i Norge 2011. Available from www.kreftregisteret.no.
   Google Scholar
• Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007;25:2035–41.
   PubMed Web of Science ®Google Scholar
• Ward JF, Zincke H, Bergstrahl EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 2004;172:2244–8.
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Colette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 2005;366:572–8.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006;296:2329–35.
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:2924–30.
   PubMed Web of Science ®Google Scholar
• Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, et al. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys 2011;77:1–7.
   Google Scholar
• Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker SL, et al. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 2005;63:134–40.
   PubMedGoogle Scholar
• Ohori M, Wheeler TN, Scardino PT. The New American Joint Committee on Cancer and International Union Against Cancer. TNM classification of prostate cancer. Clinicipathologic correlations. Cancer 1994;74:104–14.
   PubMed Web of Science ®Google Scholar
• Epstein JI, Allsbrook WC, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005;29:1228–42.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Ben-Porat L, Scher HI, Chan HM, Fearn PA, Fuks ZY, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 2005;23:826–31.
   PubMedGoogle Scholar
• Memorial Sloan Kettering Cancer Center. PSA doubling time calculator. Available from http://www.mskcc.org/mskcc/html/10088.cfm.
   Google Scholar
• Trock BJ, Han M, Freedland SJ, Humphreys EB, DeWeese TL, Partin AW, et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299:2760–9.
   PubMed Web of Science ®Google Scholar
• Trapasso JG, de Kernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152:1821–5.
   PubMed Web of Science ®Google Scholar
• Bernard JR, Buskirk SJ, Heckman MG, Diehl NN, Ko SJ, MacDonald OK, et al. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose–response analysis. Int J Radiat Oncol Biol Phys 2010;76:735–40.
   PubMed Web of Science ®Google Scholar
• Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591–7.
   PubMed Web of Science ®Google Scholar
• Maffezzini M, Bossi A, Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol 2007;51:605–13.
   PubMedGoogle Scholar
• Sandler HM, Dunn RL, McLaughlin PW, Hayman JA, Sullivan MA, Taylor JM. Overall survival after prostate-specific-antigen detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys 2000;48:629–33.
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376–83.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Radiation therapy and androgen deprivation therapy in treating patients who have undergone surgery for prostate cancer (RADICALS). Available from http://clinicaltrials.gov/show/NCT00541047.
   Google Scholar
• Leventis AK, Shariat SF, Kattan MW, Butler B, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001;19:1030–9.
   PubMed Web of Science ®Google Scholar
• Rouanne M, Rode J, Campeggi A, Allory Y, Vordos D, Hoznek A, et al. Long-term impact of positive surgical margins on biochemical recurrence after radical prostatectomy: ten years follow-up. Scand J Urol 2014;48:131–7.
   PubMed Web of Science ®Google Scholar
• Alkhateeb S, Alibhai S, Fleshner N, Finelli A, Jewett M, Zlotta A, et al. Impact of positive surgical margins after radical prostatectomy differs by risk group. J Urol 2010;183:145–50.
   PubMedGoogle Scholar
• Berg A, Berner A, Lilleby W, Bruland ØS, Fosså SD, Nesland JM, et al. Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. Int J Cancer 2007;15:1603–9.
   Google Scholar